Literature DB >> 26613169

Evidence of increased brain amyloid in severe TBI survivors at 1, 12, and 24 months after injury: report of 2 cases.

Joshua W Gatson1,2, Cari Stebbins1, Dana Mathews3, Thomas S Harris4, Christopher Madden2, Hunt Batjer2, Ramon Diaz-Arrastia5, Joseph P Minei1.   

Abstract

Traumatic brain injury (TBI) is a major risk factor for Alzheimer's disease. With respect to amyloid deposition, there are no published serial data regarding the deposition rate of amyloid throughout the brain after TBI. The authors conducted serial (18)F-AV-45 (florbetapir F18) positron emission tomography (PET) imaging in 2 patients with severe TBI at 1, 12, and 24 months after injury. A total of 12 brain regions were surveyed for changes in amyloid levels. Case 1 involved a 50-year-old man who experienced a severe TBI. Compared with the 1-month time point, of the 12 brain regions that were surveyed, a decrease in amyloid (as indicated by standard uptake value ratios) was only observed in the hippocampus (-16%, left; -12%, right) and caudate nucleus (-18%, left; -18%, right), suggesting that initial amyloid accumulation in the brain was cleared between time points 1 and 12 months after injury. Compared to the scan at 1 year, a greater increase in amyloid (+15%) was observed in the right hippocampus at the 24-month time point. The patient in Case 2 was a 37-year-old man who suffered severe trauma to the head and a subsequent stroke; he had poor cognitive/functional outcomes and underwent 1.5 years of rehabilitation. Due to a large infarct area on the injured side of the brain (right side), the authors focused primarily on brain regions affected within the left hemisphere. Compared with the 1-month scan, they only found an increase in brain amyloid within the left anterior putamen (+11%) at 12 months after injury. In contrast, decreased amyloid burden was detected in the left caudate nucleus (-48%), occipital cortex (-21%), and precuneus (-19%) brain regions at the 12-month time point, which is indicative of early accumulation and subsequent clearance. In comparison with 12-month values, more clearance was observed, since a reduction in amyloid was found at 24 months after trauma within the left anterior putamen (-12%) and occipital cortex (-15%). Also, by 24 months, most of the amyloid had been cleared and the patient demonstrated improved results on the Rivermead symptom questionnaire, Glasgow Outcome Scale-Extended, and Disability Rating Scale. With respect to APOE status, the patient in Case 1 had two ε3 alleles and the patient in Case 2 had one ε2 and one ε3 allele. In comparison to the findings of the initial scan at 1 month after TBI, by 12 and 24 months after injury amyloid was cleared in some brain regions and increased in others. Serial imaging conducted here suggests that florbetapir F18 PET imaging may be useful in monitoring amyloid dynamics within specific brain regions following severe TBI and may be predictive of cognitive deficits.

Entities:  

Keywords:  AD = Alzheimer’s disease; DRS = Disability Rating Scale; GCS = Glasgow Coma Scale; GOS-E = Glasgow Outcome Scale-Extended; MMSE = Mini-Mental State Examination; MNI = Montreal Neurological Institute; SUVR = standard uptake value ratio; TBI = traumatic brain injury; VOI = volume of interest; amyloid; florbetapir F18; traumatic brain injury

Mesh:

Substances:

Year:  2015        PMID: 26613169     DOI: 10.3171/2015.6.JNS15639

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  8 in total

Review 1.  Disordered APP metabolism and neurovasculature in trauma and aging: Combined risks for chronic neurodegenerative disorders.

Authors:  Milos D Ikonomovic; Zhiping Mi; Eric E Abrahamson
Journal:  Ageing Res Rev       Date:  2016-11-06       Impact factor: 10.895

2.  Higher exosomal tau, amyloid-beta 42 and IL-10 are associated with mild TBIs and chronic symptoms in military personnel.

Authors:  Jessica Gill; Maja Mustapic; Ramon Diaz-Arrastia; Rael Lange; Seema Gulyani; Tom Diehl; Vida Motamedi; Nicole Osier; Robert A Stern; Dimitrios Kapogiannis
Journal:  Brain Inj       Date:  2018-06-18       Impact factor: 2.311

3.  Increased rates of sequelae post-encephalitis in individuals attending primary care practices in the United Kingdom: a population-based retrospective cohort study.

Authors:  Julia Granerod; Nicholas W S Davies; Parashar P Ramanuj; Ava Easton; David W G Brown; Sara L Thomas
Journal:  J Neurol       Date:  2016-10-20       Impact factor: 4.849

4.  Spatial Patterns of Amyloid Deposition in Patients with Chronic Focal or Diffuse Traumatic Brain Injury Using 18F-FPYBF-2 PET.

Authors:  Shiho Ubukata; Naoya Oishi; Tatsuya Higashi; Shinya Kagawa; Hiroshi Yamauchi; Chio Okuyama; Hiroyuki Watanabe; Masahiro Ono; Hideo Saji; Toshihiko Aso; Toshiya Murai; Keita Ueda
Journal:  Neuropsychiatr Dis Treat       Date:  2020-11-12       Impact factor: 2.570

Review 5.  The chronic and evolving neurological consequences of traumatic brain injury.

Authors:  Lindsay Wilson; William Stewart; Kristen Dams-O'Connor; Ramon Diaz-Arrastia; Lindsay Horton; David K Menon; Suzanne Polinder
Journal:  Lancet Neurol       Date:  2017-09-12       Impact factor: 59.935

6.  CHIMERA repetitive mild traumatic brain injury induces chronic behavioural and neuropathological phenotypes in wild-type and APP/PS1 mice.

Authors:  Wai Hang Cheng; Kris M Martens; Asma Bashir; Honor Cheung; Sophie Stukas; Ebrima Gibbs; Dhananjay R Namjoshi; Emily B Button; Anna Wilkinson; Carlos J Barron; Neil R Cashman; Peter A Cripton; Cheryl L Wellington
Journal:  Alzheimers Res Ther       Date:  2019-01-12       Impact factor: 6.982

Review 7.  Traumatic Axonal Injury: Mechanisms and Translational Opportunities.

Authors:  Ciaran S Hill; Michael P Coleman; David K Menon
Journal:  Trends Neurosci       Date:  2016-03-31       Impact factor: 13.837

8.  Moderate/severe traumatic brain injury as a trigger of chronic neurodegeneration in humans.

Authors:  Sergio Bagnato; Cristina Boccagni
Journal:  Neural Regen Res       Date:  2020-07       Impact factor: 5.135

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.